9 Papers
78 Citations
Mark Schulz is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Catalysis & Dibutyltin oxide. The author has an hindex of 6, co-authored 9 publications. Previous affiliations of Mark Schulz include Janssen Pharmaceutica & Johnson & Johnson.
Chat about Author
Papers
Microwave-Assisted Preparation of Aryltetrazoleboronate Esters
TL;DR: The addition of azido trimethylsilane to arylnitrileboronate esters is shown to proceed rapidly in dimethoxyethane to give aryltetrazoleboronates esters in moderate to good yields, with dibutyltin oxide as catalyst.
36
Patent
Prokineticin 2 receptor antagonists
Steven J. Coats,Alexey B. Dyatkin,Wei He,Joseph G. Lisko,Tamara A. Miskowski,Janet L. Ralbovsky,Mark Schulz +6 more
- 28 Dec 2006
TL;DR: In this article, the authors present methods for the treatment of prokineticin 2 or prokinetin 2 receptor mediated disorders. But the present method is not suitable for certain novel compounds of Formula (I):
29
Patent
Pyrimidindione derivatives as prokineticin 2 receptor antagonists
Steven J. Coats,Alexey B. Dyatkin,He Wei,Joseph G. Lisko,Tamara A. Miskowski,Janet L. Ralbovsky,Mark Schulz +6 more
- 14 Mar 2006
TL;DR: In this article, certain novel compounds of Formula (I) which are suitable for the treatment of prokineticin 2 or prokinetin 2 receptor mediated disorders were presented.
21
Triazinediones as prokineticin 1 receptor antagonists. Part 1: SAR, synthesis and biological evaluation.
Janet L. Ralbovsky,Joseph G. Lisko,Jeffrey M. Palmer,John R. Mabus,Kristen M. Chevalier,Mark Schulz,Alexey B. Dyatkin,Tamara A. Miskowski,Steven J. Coats,Pamela J. Hornby,Wei He +10 more
TL;DR: A series of guanidine triazinediones were identified as potent PK1 receptor antagonists and inhibited the PK1 invoked prosecretory response in rat ileum tissue.
15
Patent
Amino-heteroaryl-containing prokineticin 1 receptor antagonists
Steven J. Coats,Alexey B. Dyatkin,Wei He,Joseph G. Lisko,Tamara A. Miskowski,Janet L. Ralbovsky,Mark Schulz +6 more
- 23 Oct 2008
TL;DR: In this paper, the authors present methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of prokineticin 1 or prokinetin 1 receptor mediated disorders.
11